3 results
To determine the rate of detection of sub-clinical atrial AF (* 5 minutes) within an average of 12 months following implant of the Confirm® Implantable Cardiac Monitor in patients with known cardiovascular risk factors and left atrial enlargement,…
The primary objective of this study is to determine the safety, tolerability and efficacy of AR101 characterized oral desensitization immunotherapy (CODITTM) using alternative maintenance dosing intervals.The secondary objectives are:* To confirm…
The primary objective is to demonstrate the efficacy of AR101, a pharmaceutical-grade peanut allergen formulation, through reduction in clinical reactivity to limited amounts of peanut allergen in peanut-allergic children (ages 4-17 years, inclusive…